Nate Kingsbury
About Nate Kingsbury
Nate Kingsbury is a Senior Process Engineer II at Kite Pharma, specializing in the design and optimization of viral vector manufacturing processes. He has extensive experience in implementing cGxP principles in cell-mediated therapies and has held various research and engineering positions in the biotechnology field.
Work at Kite Pharma
Nate Kingsbury serves as a Senior Process Engineer II at Kite Pharma, a position he has held since 2018. In this role, he specializes in the design and optimization of viral vector manufacturing processes. His work contributes to the development of cell-mediated therapies, focusing on the implementation of current Good Manufacturing Practice (cGxP) principles. Kingsbury's expertise is essential in advancing Kite Pharma's mission to create innovative cancer therapies.
Education and Expertise
Nate Kingsbury earned his Ph.D. in Chemical Engineering from the University of California, Davis, where he studied from 2008 to 2013. He also holds a Bachelor of Science in Bioengineering with a pharmaceutical track from Lehigh University, completed from 2004 to 2008. His academic background provides a strong foundation for his expertise in cell-mediated therapies and viral vector manufacturing processes.
Background
Nate Kingsbury's professional journey includes various roles in the biotechnology sector. He began his career as a Student Intern at Pall Life Sciences in 2006 and later held positions at the Massachusetts BioManufacturing Center and the University of Massachusetts Amherst as a Postdoctoral Researcher. His experience also includes roles at MilliporeSigma as a Process Development Scientist and Process Characterization Specialist, where he gained valuable insights into process optimization.
Achievements
Throughout his career, Nate Kingsbury has contributed to the development of novel cell therapies that focus on genetically engineering immune cells to target cancer cells. His work in implementing cGxP principles has been pivotal in ensuring compliance and quality in the development of these therapies. Kingsbury's contributions reflect his commitment to advancing the field of biotechnology and improving patient outcomes.